ESTRO 2023 - Abstract Book

S1290

Digital Posters

ESTRO 2023

PO-1589 Clinical outcomes of two radiotherapy schedules for spinal cord compression

M. Hernandez Miguel 1 , J. Romero Fernández 1 , R. Benlloch Rodríguez 1 , B. Gil Haro 1 , M. López Valcárcel 1 , C. de la Fuente Alonso 1 , J. Velasco Jiménez 1 , S. Córdoba Largo 1 , M.I. García Berrocal 1 , I. Zapata Paz 1 , M.R. Magallón Sebastian 1 , P. Sarrión Rubio de la Torre 1 , S. Santana Jiménez 1 , S. Pérez Mata 1 , F.J. Martínez Paredes 1 , M.Á. Ruíz Rodríguez 1

1 University Hospital Puerta de Hierro, Radiation Oncology, Madrid, Spain

Purpose or Objective To compare pain improvement, spinal cord compression (SCC) signs and overall survival (OS) between two radiotherapy schedules: 20Gy in 5 fractions (RT20) and 30Gy in 10 fractions (RT30). Materials and Methods Between January-2016 to December-2021, 204 patients with clinical or radiological SCC were treated with radiotherapy. One hundred and twenty four patients were male (60.8%) and 80 patients were female (39.2%). Median age was 65 years (range 35-90). Most frequent localization was thoracic spine (169 patients; 82.8%), lumbar spine (57 patients; 27.9%) and cervical spine (32 patients; 15.7%). Most frequent primary tumours were lung (68 patients), breast (40 patients) and prostate cancer (33 patients). One hundred and eight patients were treated with RT20 schedule (52.9%) and 96 patients with RT30 schedule (47.1%).

All patients were treated within 24h from radiological diagnosis by MRI.

Statistics: Student T, chi-square and Kaplan-Meier.

Results One-hundred and seventy-three patients experienced symptoms or SCC signs (84.8%). The most common symptom was pain (172 patients; 84.3%) followed by motor deficits (43 patients; 21.1%), sensory deficits (25 patients; 12.3%) and autonomic dysfunction (3 patients; 1.5%). Radiotherapy significantly improves pain (mean VAS before treatment was 7.13 vs 3.24 after treatment; p<0.001). There were no differences in pain relief or recovery from SCC signs between both schemes.

A better 2-year OS was seen in breast cancer patients (28.7% vs 17.6% and 9.5% for prostate and lung cancer, respectively; p=0.001) (figure1).

Furthermore, better OS was observed for the RT30 schedule (23.8% vs 7.6% for RT20; p<0.001).